Sonoma Pharmaceuticals Q2 revenue beats expectations on increased distributor sales

Reuters11-04

Sonoma Pharmaceuticals <a href="https://laohu8.com/S/QTWO">Q2</a> revenue beats expectations on increased distributor sales

Overview

Sonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectations
Net loss per share decreases 46% for fiscal Q2 compared to last year
U.S. revenue increases 115% for fiscal Q2, driven by OTC product sales

Outlook

Company expects positive growth trajectory with increasing product adoption

Result Drivers

U.S. SALES GROWTH - Revenue in the U.S. increased 115% due to higher sales of OTC products and increased distributor sales
NEW PRODUCT LAUNCHES - Launch of HOCl-based diaper rash products and other new products contributed to revenue growth
REGULATORY MILESTONES - Key regulatory clearances, including FDA registration, supported growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$5.60 mln	$4.26 mln (1 Analyst)
Q2 EPS		-$0.32
Q2 Net Income		-$500,000
Q2 EBITDA		-$200,000
Q2 Gross Profit		$2.10 mln
Q2 Operating Expenses		$2.50 mln

Analyst Coverage

The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 74.5% above its November 3 closing price of $3.78

Press Release: ID:nACSQC7GQa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580359730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580359730","market":"us","top_or_hot":-1,"title":"Sonoma Pharmaceuticals Q2 revenue beats expectations on increased distributor sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sonoma Pharmaceuticals <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations on increased distributor sales</title></head><body><p><span>Overview</span></p><ul><li><p>Sonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectations</p></li><li><p>Net loss per share decreases 46% for fiscal Q2 compared to last year</p></li><li><p>U.S. revenue increases 115% for fiscal Q2, driven by OTC product sales</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects positive growth trajectory with increasing product adoption</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. SALES GROWTH - Revenue in the U.S. increased 115% due to higher sales of OTC products and increased distributor sales</p></li><li><p>NEW PRODUCT LAUNCHES - Launch of HOCl-based diaper rash products and other new products contributed to revenue growth</p></li><li><p>REGULATORY MILESTONES - Key regulatory clearances, including FDA registration, supported growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$5.60 mln</p></td><td><p>$4.26 mln (1 Analyst)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.32</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$500,000</p></td><td></td></tr><tr><td><p>Q2 EBITDA</p></td><td></td><td><p>-$200,000</p></td><td></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$2.10 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$2.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"strong buy\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 74.5% above its November 3 closing price of $3.78</p></li></ul><p>Press Release: <span>ID:nACSQC7GQa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonoma Pharmaceuticals Q2 revenue beats expectations on increased distributor sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonoma Pharmaceuticals Q2 revenue beats expectations on increased distributor sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sonoma Pharmaceuticals <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations on increased distributor sales</title></head><body><p><span>Overview</span></p><ul><li><p>Sonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectations</p></li><li><p>Net loss per share decreases 46% for fiscal Q2 compared to last year</p></li><li><p>U.S. revenue increases 115% for fiscal Q2, driven by OTC product sales</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects positive growth trajectory with increasing product adoption</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. SALES GROWTH - Revenue in the U.S. increased 115% due to higher sales of OTC products and increased distributor sales</p></li><li><p>NEW PRODUCT LAUNCHES - Launch of HOCl-based diaper rash products and other new products contributed to revenue growth</p></li><li><p>REGULATORY MILESTONES - Key regulatory clearances, including FDA registration, supported growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$5.60 mln</p></td><td><p>$4.26 mln (1 Analyst)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.32</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$500,000</p></td><td></td></tr><tr><td><p>Q2 EBITDA</p></td><td></td><td><p>-$200,000</p></td><td></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$2.10 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$2.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"strong buy\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 74.5% above its November 3 closing price of $3.78</p></li></ul><p>Press Release: <span>ID:nACSQC7GQa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0QX:1","article_id":"2580359730","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580359730","pubTimestamp":1762265067,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sonoma PharmaceuticalsQ2 revenue beats expectations on increased distributor salesOverviewSonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectationsNet loss per share decreases 46% for fis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","BK4007":"制药","SNOA":"Sonoma Pharmaceuticals, Inc."},"translate_title":"索诺玛制药第二季度收入因经销商销售额增加而超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNOA":0.9},"content_text":"Sonoma Pharmaceuticals Q2 revenue beats expectations on increased distributor salesOverviewSonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectationsNet loss per share decreases 46% for fiscal Q2 compared to last yearU.S. revenue increases 115% for fiscal Q2, driven by OTC product salesOutlookCompany expects positive growth trajectory with increasing product adoptionResult DriversU.S. SALES GROWTH - Revenue in the U.S. increased 115% due to higher sales of OTC products and increased distributor salesNEW PRODUCT LAUNCHES - Launch of HOCl-based diaper rash products and other new products contributed to revenue growthREGULATORY MILESTONES - Key regulatory clearances, including FDA registration, supported growthKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$5.60 mln$4.26 mln (1 Analyst)Q2 EPS-$0.32Q2 Net Income-$500,000Q2 EBITDA-$200,000Q2 Gross Profit$2.10 mlnQ2 Operating Expenses$2.50 mlnAnalyst CoverageThe one available analyst rating on the shares is \"strong buy\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 74.5% above its November 3 closing price of $3.78Press Release: ID:nACSQC7GQaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580359730","isCrawlerRequest":true}